How Much Does Belsomra (Suvorexant) Cost in Nevada in 2026?

Nevada Retail Pricing for Belsomra in 2026

The gap between what Merck lists and what Nevada patients actually pay is wide. Merck's wholesale acquisition cost remains $340 per month for a 30-tablet supply of Belsomra at any approved dose strength. At Nevada retail pharmacies, the average uninsured cash price has dropped to roughly $85 per month in 2026, according to aggregated pharmacy pricing data across Las Vegas, Reno, and Henderson locations.

That $85 figure reflects negotiated rates through discount platforms and pharmacy benefit managers. Without any coupon or discount card, some independent Nevada pharmacies still charge $280 to $320 per month. Prices vary by as much as $150 between pharmacies in the same zip code. Chain pharmacies like CVS, Walgreens, and Smith's (Kroger) in Clark County tend to cluster closer to the $85 to $110 range when patients use a free discount card at checkout.

Suvorexant was the first dual orexin receptor antagonist (DORA) approved by the FDA in August 2014 for the treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance. In the key trial by Herring et al. (Lancet Neurology, 2014), suvorexant at doses of 40 mg and 20 mg significantly improved subjective total sleep time versus placebo over four weeks, with the 40/30 mg group gaining 22 minutes of additional sleep on polysomnography at month one (P<0.0001, N=1,021).

No generic suvorexant exists in 2026. Merck's patent protection extends into the late 2020s, and no Abbreviated New Drug Application for a generic version has been approved by the FDA as of this writing.

Why Nevada Medicaid Does Not Cover Belsomra

Nevada Medicaid's preferred drug list excludes Belsomra. The Nevada Department of Health and Human Services maintains a formulary through its pharmacy benefit manager that favors older, less expensive insomnia treatments. Preferred alternatives on the Nevada Medicaid formulary include generic zolpidem (Ambien), generic eszopiclone (Lunesta), and generic trazodone.

Patients enrolled in Nevada Medicaid who want Belsomra specifically must pursue a prior authorization. Success rates for these requests are low. The prescriber needs to document failure of, or contraindication to, at least two preferred agents before the state will consider covering a non-formulary sleep medication. Even then, approval is not guaranteed.

The American Academy of Sleep Medicine's 2017 clinical practice guideline recommends suvorexant as a treatment option for sleep maintenance insomnia in adults, noting that the recommendation was based on evidence from randomized controlled trials showing statistically significant improvements in wake after sleep onset. The AASM panel rated the quality of evidence as "moderate" for sleep maintenance and "low" for sleep onset when suvorexant is used at the FDA-approved dose range of 10 to 20 mg.

For Medicaid patients who are denied, switching to a covered DORA may be worth discussing with the prescriber. Lemborexant (Dayvigo), another orexin antagonist, may have different formulary status depending on the managed care organization administering the patient's Medicaid benefits.

Compounded Suvorexant in Nevada: Legal Status and Pricing

Compounded suvorexant is legal in Nevada when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Nevada Board of Pharmacy regulations permit 503A pharmacies to compound medications that are commercially available, provided certain conditions are met: the prescriber documents a medical need for a compounded formulation, and the pharmacy follows USP <795> standards for non-sterile compounding.

The practical reasons patients seek compounded suvorexant include dose customization (such as a 7.5 mg or 12.5 mg dose not commercially available), difficulty swallowing tablets, or cost reduction. Compounded pricing varies by pharmacy but is often significantly lower than brand Belsomra. Some Nevada compounding pharmacies advertise suvorexant preparations at $40 to $65 per month, though pricing is not standardized and depends on the source of bulk suvorexant powder, which must meet USP-grade purity requirements.

Patients considering compounded suvorexant should verify the pharmacy's Nevada Board of Pharmacy license and ask whether the pharmacy holds PCAB accreditation or similar quality certification. A 2019 FDA survey of compounded drugs found that roughly 28% of tested preparations failed quality testing for potency, sterility, or content uniformity, reinforcing the importance of selecting an accredited compounder.

503B outsourcing facilities operate under a different regulatory framework and may distribute compounded suvorexant without patient-specific prescriptions, but these facilities must register with the FDA and comply with current good manufacturing practice requirements. As of 2026, no 503B facility has registered suvorexant as a routinely compounded product.

Insurance Coverage for Belsomra Across Nevada Plans

Coverage varies sharply across Nevada's commercial insurance market. Plans offered through the Nevada Health Link (the state's ACA marketplace) may or may not include Belsomra on their formulary. Among the major carriers active in Nevada in 2026, coverage breaks down roughly as follows.

UnitedHealthcare plans in Nevada typically place Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $50 to $90 per month after deductible. Anthem Blue Cross Blue Shield Nevada plans vary by metal level; Gold and Platinum plans more frequently cover Belsomra with a $40 to $75 copay, while Bronze plans may require full cost until the deductible is met.

Health Plan of Nevada (HPN), a subsidiary of UnitedHealth Group and one of the largest managed care organizations in the state, requires prior authorization for Belsomra. The PA criteria generally require documentation that the patient has tried and failed generic zolpidem or eszopiclone.

A 2023 analysis published in JAMA Network Open found that among commercially insured adults with insomnia, out-of-pocket costs for brand-name sleep medications averaged $62 per fill for patients with prior authorization approval, compared to $27 per fill for generic alternatives. The study examined claims data from over 8.2 million insured individuals across the United States.

Employer-sponsored plans in Nevada represent another pathway. Large employers such as MGM Resorts, Caesars Entertainment, and the State of Nevada's Public Employees' Benefits Program (PEBP) each maintain distinct formularies. PEBP, which covers approximately 70,000 state employees and dependents, places Belsomra behind a step-therapy requirement as of its 2025-2026 plan year.

The Merck Savings Card and Other Discount Programs

Merck offers a Belsomra savings card that reduces out-of-pocket costs for commercially insured patients to as low as $15 per month. The card is not available to patients enrolled in Medicare, Medicaid, Tricare, or any other federal or state government-funded program. Nevada residents with commercial insurance can enroll on the Belsomra HCP website or through their prescriber's office.

The savings card has an annual cap, typically $3,400 per calendar year. For most patients filling one prescription per month, this cap is sufficient to cover 12 months of reduced copays. The card works by covering the difference between the patient's copay and $15, up to the annual maximum.

Free discount cards from platforms like GoodRx, RxSaver, and SingleCare regularly bring the cash price below $100 at Nevada pharmacies. These cards are free to use, require no insurance, and work at most chain pharmacies in the state. GoodRx pricing at Nevada Walgreens and CVS locations as of early 2026 ranges from $78 to $95 for a 30-day supply of Belsomra 10 mg or 20 mg.

Dr. Michael Grandner, Director of the Sleep and Health Research Program at the University of Arizona, has noted: "Cost is one of the most common barriers to insomnia treatment adherence. When patients can't afford their medication, they either stop taking it or never fill the prescription in the first place, which perpetuates the cycle of chronic insomnia."

Patient assistance programs through NeedyMeds and RxAssist may also help uninsured or underinsured Nevada residents access Belsomra at no cost. Merck's own patient assistance program provides free Belsomra to qualifying patients with household incomes below 400% of the federal poverty level.

Telehealth Prescribing of Belsomra in Nevada

Nevada permits telehealth prescribing of Belsomra. A provider licensed in Nevada can evaluate a patient via synchronous audio-video visit and prescribe suvorexant if clinically appropriate. The prescription is then transmitted electronically to any Nevada pharmacy.

The Ryan Haight Act historically required an in-person evaluation before prescribing controlled substances via telehealth. Suvorexant is a Schedule IV controlled substance under the federal Controlled Substances Act. The DEA's post-pandemic telemedicine flexibilities, codified through final rulemaking in 2025, now permit initial prescribing of Schedule III-V substances via telehealth without a prior in-person visit, provided the prescriber conducts a real-time audio-video evaluation and complies with state-specific rules.

Nevada's telemedicine statutes (NRS 629.515 and related provisions) align with these federal flexibilities. Nevada-licensed prescribers may prescribe Belsomra after a telehealth encounter without requiring the patient to visit a brick-and-mortar clinic first. This is particularly relevant for patients in rural Nevada counties like Elko, Nye, and Humboldt, where sleep medicine specialists are scarce.

The National Institutes of Health reports that approximately 50 to 70 million American adults have a sleep disorder, with insomnia being the most common. In Nevada, access to board-certified sleep medicine physicians is limited: the state has roughly 35 sleep medicine specialists for a population of over 3.2 million, concentrating most expertise in Clark and Washoe counties.

Telehealth platforms operating in Nevada that may prescribe Belsomra include HealthRX, Cerebral, Done, and various hospital-affiliated telemedicine services through Renown Health and UMC.

How Belsomra Compares to Other Nevada-Available Sleep Medications on Cost

Price context matters when deciding whether Belsomra is worth the out-of-pocket expense. Generic zolpidem (5 mg and 10 mg) costs $4 to $12 per month at most Nevada pharmacies. Generic eszopiclone runs $15 to $30 per month. Generic trazodone, frequently used off-label for insomnia, costs $4 to $8 per month.

Lemborexant (Dayvigo), the other commercially available DORA, carries a list price of approximately $400 per month, with cash-pay pricing at Nevada pharmacies near $95 to $120 per month with discount cards. Quviviq (daridorexant), approved in 2022, lists at roughly $450 per month and retails for $110 to $140 in Nevada with coupons.

The clinical rationale for choosing a DORA over a benzodiazepine receptor agonist like zolpidem includes a different side-effect profile. DORAs do not carry the same risk of complex sleep behaviors (sleep-driving, sleep-eating) that prompted the FDA to add a boxed warning to zolpidem, eszopiclone, and zaleplon in 2019. In the Herring et al. trial, the most common adverse event with suvorexant was somnolence, reported in 7% of the treatment group versus 3% of placebo (N=1,021) [1].

A 2020 meta-analysis in the Annals of Internal Medicine evaluated pharmacologic treatments for chronic insomnia disorder and found that suvorexant significantly improved sleep onset latency and wake after sleep onset compared with placebo, with a number needed to treat of approximately 8 for clinically meaningful improvement in subjective total sleep time. The analysis included data from over 11,000 participants across 36 randomized controlled trials.

Dr. Andrew Krystal, Professor of Psychiatry and Behavioral Sciences at UCSF, has stated: "Orexin receptor antagonists represent a mechanistically distinct approach to insomnia. They target wakefulness-promoting pathways rather than broadly sedating the brain, which may translate to a more favorable long-term safety profile compared with older hypnotics."

For Nevada patients weighing cost against clinical benefit, the decision tree often starts with insurance status. Insured patients with prior authorization approval and the Merck savings card may pay as little as $15 per month. Uninsured patients using discount cards pay roughly $85. Patients open to compounding can find pricing between $40 and $65.